20. The Role of Hematopoietic Stem-Cell Transplantation in Adults with Acute Lymphoblastic Leukemia

  1. Stefan Faderl MD Associate Professor and
  2. Hagop Kantarjian MD Chairman Professor
  1. Partow Kebriaei MD Associate Professor of Medicine

Published Online: 4 JAN 2011

DOI: 10.1002/9781444327359.ch20

Leukemias: Principles and Practice of Therapy

Leukemias: Principles and Practice of Therapy

How to Cite

Kebriaei, P. (2010) The Role of Hematopoietic Stem-Cell Transplantation in Adults with Acute Lymphoblastic Leukemia, in Leukemias: Principles and Practice of Therapy (eds S. Faderl and H. Kantarjian), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444327359.ch20

Editor Information

  1. Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Author Information

  1. University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA

Publication History

  1. Published Online: 4 JAN 2011
  2. Published Print: 26 NOV 2010

ISBN Information

Print ISBN: 9781405182355

Online ISBN: 9781444327359

SEARCH

Keywords:

  • hematopoietic stem cell transplantation;
  • acute lymphoblastic leukemia

Summary

Adult patients with acute lymphoblastic leukemia (ALL) can now achieve complete remission (CR) rates of 80–90%. However, only 25–50% of these patients achieve long-term disease-free survival. Current research efforts are focused on innovative post-remission strategies with the goal of improving disease-free survival (DFS) and overall survival (OS). The identification of different prognostic groups based on the biology of the malignant clone and well-characterized prognostic factors allows for risk-adapted therapy. Multiple randomized trials have demonstrated that allogeneic hematopoietic stem cell transplantation (SCT) improves the outcome of patients with high-risk ALL. Furthermore, recent trials suggest that patients with standard-risk ALL may also benefit from allogeneic SCT. In this chapter, we will define the different disease risk groups, the clinical outcomes of major transplant trials for ALL, and the therapeutic factors that affect outcome following SCT.